Life Sciences DNA Podcast – Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

Life Sciences DNA Podcast

Levine Media Group

Science

Business

Frequency: 1 episode/18d. Total Eps: 49

The Life Sciences D’n’A podcast is hosted by AI and data analytics experts and pharma industry veterans Nagaraja Srivatsan and Amar Drawid. They explore the evolving use of AI and data science with innovators working to reshape all aspects of the biopharmaceutical industry from the way new therapeutics are discovered to how they are marketed.

Read moreCollapse

Site

RSS

Apple

Data updated on 04/07/2026

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

🇺🇸 USA - Life Sciences
27/08/2026
#88
🇬🇧 Great Britain - Life Sciences
09/06/2026
#99
🇬🇧 Great Britain - Life Sciences
08/06/2026
#84
🇬🇧 Great Britain - Life Sciences
07/06/2026
#68
🇬🇧 Great Britain - Life Sciences
05/06/2026
#43
🇬🇧 Great Britain - Life Sciences
04/06/2026
#26
🇬🇧 Great Britain - Life Sciences
03/06/2026
#78
🇬🇧 Great Britain - Life Sciences
02/06/2026
#70
🇬🇧 Great Britain - Life Sciences
01/06/2026
#60
🇬🇧 Great Britain - Life Sciences
31/05/2026
#44

Spotify

No recent rankings available

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

https://cloud.google.com/resources/content/roi-of-ai-healthcare-life-sciences
2 shares

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

RSS feed quality

To improve

Score global : 37%

Publication history

Monthly episode publishing history over the past years.

Year

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

Human Accountability in an Agentic Pharma World

Episode 51

Thursday, May 28, 2026 • Duration 49:05

Vertex senior director Amrit Moola sits down with Srivatsan Nagaraja to discuss what it takes to operationalize AI in pharma and biotech from early experiments to large‑scale transformation. He describes how to pick high‑impact use cases, re‑architect processes around agents and real‑time data, and align business operations on outcomes. The discussion ranges from CRO recruitment data and batch disposition in cell and gene therapy to guardrails, governance, and why you can’t blame the algorithm when something goes wrong.

Read moreCollapse

Making AI Transformations that Stick

Episode 50

Thursday, May 14, 2026 • Duration 53:11

Vikram Nair, chief information officer of Amneal Pharmaceuticals, joins Srivatsan Nagaraja to break down what it really takes to turn AI from boardroom buzz into real business impact. From early missteps and skeptical stakeholders to building smarter metrics, Nair shares lessons from the front lines of AI transformation—and introduces a practical control framework to help life sciences companies scale AI, manage risk, and evolve without losing control.

Read moreCollapse

Finding ROI from AI in the Mundane

Episode 48

Thursday, April 9, 2026 • Duration 46:18

Dennis Salotti, executive director and head of clinical outsourcing and innovation at Jazz Pharmaceuticals, joins Srivatsan Nagaraja to talk about what AI really looks like in day-to-inside a drug company. He explains how large language models and agentic tools can streamline contracting, budgeting, and risk management—mundane but high-impact work that speeds studies and improves trial-site experience. Salotti shares how to design narrow, high‑ROI pilots, build AI fluency, avoid “AI slop,” and turn AI into a thinking partner rather than a shortcut, stacking small wins that remove grunt work, capture lessons learned, and elevate people from doers to critical thinkers.

Read moreCollapse

A Pragmatic Path to AI-Enabled Commercial Operations

Episode 47

Thursday, March 26, 2026 • Duration 36:41

Tris Pharma Chief Commercial Officer Manesh Naidu sits down with Nagaraja Srivatsan to discuss how the small but growing specialty pharma company is pursuing a deliberately incremental AI strategy, focusing on its biggest pain points rather than chasing grand, enterprise-wide transformations. He explains how the team is using off-the-shelf and vendor tools where possible, rigorously managing data and compliance risk, and letting quick wins in discrete use cases pave the way for broader change. Naidu discusses what practical AI adoption looks like for Tris, how the company is applying the technology to high-value commercial challenges, and how it is reinventing sales training through virtual physician simulations.

Read moreCollapse

Reimagining Scientific Work in the Age of AI Agents

Episode 46

Thursday, March 12, 2026 • Duration 47:28

Shweta Maniar, global strategy and market leader for life sciences at Google Cloud, sits down with Nagaraja Srivatsan to unpack what it takes to turn AI pilots into durable, enterprise-wide impact. A former biotech executive who now helps biopharma leaders modernize their data and AI strategy, Shweta argues that success starts with fixing fragmented data foundations and reshaping culture—not just deploying the latest model. She explains why AI should be treated as a strategic upgrade to de-risk science rather than a narrow tool for squeezing efficiency, why the hardest problems are less about model performance and more about data and organizational behavior, and how emerging multi-agent systems could compress timelines from discovery to patient access. You can download The ROI of AI in Healthcare and Life Sciences report referenced in the discussion here: https://cloud.google.com/resources/content/roi-of-ai-healthcare-life-sciences

Read moreCollapse

Orchestrating Scientists, Data, and AI to Discover New Drugs

Episode 45

Thursday, February 26, 2026 • Duration 46:11

Scotch McClure had a bold plan for Maxwell Biosciences to map and mine the roughly 3 percent of peptides circulating in human plasma. The company has harnessed AI to move from a massive and messy universe of human peptides to a small-molecule candidate that could offer a potential alternative to antibiotics, antifungals, and some antivirals. McClure, CEO of Maxwell, sat down with Nagaraja Srivatsan to discuss why he thinks AI is becoming the central engine that makes modern drug development not just faster but possible at all, how he sees AI as essential to filtering out the noise in vast datasets, and why organizations will need to surrender more of the scientific process to AI while constraining it with a clear vision and guardrails.

Read moreCollapse

Scaling Practical AI Across Commercial Teams

Episode 44

Thursday, February 12, 2026 • Duration 48:55

Drew McCormick, head of data and analytics at Eversana, sits down with Nagaraja Srivatsan to trace the company’s AI journey from classic predictive modeling in its data and analytics business to an enterprise-wide strategy. He describes how Eversana is building on a strong data foundation to tackle challenges such as patient identification, while also rethinking workflows, governance, and talent to ensure AI delivers value in a highly regulated environment.

Read moreCollapse

Building an AI-Ready Biopharma Organization

Episode 42

Thursday, January 8, 2026 • Duration 54:51

Scott Cenci, chief information and data officer for Acadia Pharmaceuticals, sits down with Nagaraja Srivatsan to discuss how generative and agentic AI are reshaping biopharma throughout the enterprise from R&D and clinical development to the commercial field. He discusses how it is changing the roles of people like medical writers into medical editors, why every knowledge worker will soon manage AI agents as part of their job; and the hard problems leaders face in prioritizing AI investments, avoiding experiment fatigue, governing enterprise data, and building a culture of continuous learning.

Read moreCollapse

Automating Biopharma Workflows with AI and Robotics

Episode 41

Wednesday, December 24, 2025 • Duration 37:48

Karthik Raman, co-founder and CEO of Persist AI, sits down with the Nagaraja Srivatsan to discuss how robotics, AI, and cloud tech are supercharging drug formulation to address a bottleneck in pharma R&D. He explains how robots outperform humans in consistency and scale, igniting a flywheel of faster prototyping, richer data, and AI-orchestrated workflows that will propel biopharma innovation amid rising drug complexity.

Read moreCollapse

De-Risking Discovery and Improving the Success Rates of Drug Development with AI

Episode 40

Thursday, December 11, 2025 • Duration 42:03

Gabi Tarcic, vice president of product for Evogene, sits down with Srivatsan Nagaraja about applying AI to small molecule drug discovery, the cultural and operational changes required for researchers to adopt these tools, and how AI-driven platforms can improve the efficiency of pharma R&D.

Read moreCollapse

Life Sciences DNA Podcast – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Life Sciences DNA Podcast – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

Cloud Provider1

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Cloud Provider1

Apple Podcasts

Spotify